新兴和流行病原体:从临床研究网络中吸取的教训
Robert L Atmar1, Getahun Abate2, Meagan E Deming3
1Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.
概括
疫苗治疗和评估单位 (VTEUs) 网络对新出现的传染病进行临床试验. 这些研究加速了重要的疫苗和治疗方法的开发,以保护公众健康.
科学领域:
- 公共卫生和传染病.
- 临床疫苗学和治疗学
背景情况:
- 新兴和重新出现的病原体对全球健康构成重大威胁,需要强大的研究基础设施.
- 美国国家过敏和传染病研究所已经支持疫苗治疗和评估单位 (VTEUs) 超过五十年来,以应对传染病的挑战.
研究的目的:
- 审查VTEU自2000年以来进行的临床研究,重点关注新出现的病原体,流行病威胁和生物恐怖分子.
- 突出VTEU网络在评估候选疫苗和治疗药物的安全性和免疫性方面的作用.
主要方法:
- 在VTEU网络中进行的临床研究 (1-3阶段) 审查,包括疫苗,治疗药物和流行病学调查.
- 分析VTEU对预防和治疗疾病的国家和国际指南的贡献.
主要成果:
- VTEU进行的试验为许多传染病原体提供了关键的公共卫生建议.
- 该网络在严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 鉴定后三个月内迅速启动了针对2019年新冠病毒病 (COVID-19) 的研究.
结论:
- 维特欧网络是应对新兴传染病的不可或缺的公共卫生资源.
- VTEU对于加速开发和部署安全有效的医疗对策至关重要.
相关概念视频
Steps in Outbreak Investigation
488
In the ever-evolving field of public health, statistical analysis serves as a cornerstone for understanding and managing disease outbreaks. By leveraging various statistical tools, health professionals can predict potential outbreaks, analyze ongoing situations, and devise effective responses to mitigate impact. For that to happen, there are a few possible stages of the analysis:
488
Principles of Disease Surveillance
466
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
466
Infection
11.8K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
11.8K
Healthcare Associated Infections II: Preventive Measures
3.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.6K
Factors Affecting the Risk of Infection
13.2K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
13.2K
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K


